Physician profile
John D Rundquist
NPI 1386611358
$1,998.64
in general payments reported to CMS, 2019-2025
12 companies · $558 in 2025
The $558 reported for 2025 was more than what 86% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $143 · 2021: $171 · 2022: $432 · 2023: $229 · 2024: $258 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.57 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reichert, INC. | $500.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $375.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.82 | 2019-2021 | |
| Biotissue Holdings INC. | $257.50 | 2024 | |
| Spark Therapeutics, INC. | $119.69 | 2019 | |
| Coopervision INC. | $115.75 | 2021-2025 | Clariti Contact Lens |
| Lkc Technologies, INC. | $95.50 | 2023 | |
| Alcon Vision LLC | $86.00 | 2023 | Total30 |
| Topcon Healthcare, INC. | $57.19 | 2022 | |
| Bausch & Lomb Americas INC. | $47.07 | 2023 | Infuse |
| Sun Pharmaceutical Industries INC. | $34.45 | 2020 | |
| Maculogix, INC. | $16.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rundquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.